Collegium Pharmaceutical, Inc. (NASDAQ:COLL) Shares Purchased by Values First Advisors Inc.

Values First Advisors Inc. boosted its stake in Collegium Pharmaceutical, Inc. (NASDAQ:COLL) by 6.6% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 16,993 shares of the specialty pharmaceutical company’s stock after buying an additional 1,057 shares during the quarter. Values First Advisors Inc. owned approximately 0.05% of Collegium Pharmaceutical worth $547,000 at the end of the most recent reporting period.

Other institutional investors also recently bought and sold shares of the company. Assenagon Asset Management S.A. lifted its stake in shares of Collegium Pharmaceutical by 411.1% in the second quarter. Assenagon Asset Management S.A. now owns 362,137 shares of the specialty pharmaceutical company’s stock worth $11,661,000 after buying an additional 291,286 shares in the last quarter. LSV Asset Management boosted its holdings in shares of Collegium Pharmaceutical by 188.7% during the 1st quarter. LSV Asset Management now owns 380,551 shares of the specialty pharmaceutical company’s stock worth $14,773,000 after purchasing an additional 248,751 shares during the last quarter. New York State Common Retirement Fund grew its position in shares of Collegium Pharmaceutical by 1,475.5% in the fourth quarter. New York State Common Retirement Fund now owns 201,112 shares of the specialty pharmaceutical company’s stock valued at $6,190,000 after purchasing an additional 188,347 shares in the last quarter. Federated Hermes Inc. increased its holdings in shares of Collegium Pharmaceutical by 76.0% in the fourth quarter. Federated Hermes Inc. now owns 212,768 shares of the specialty pharmaceutical company’s stock valued at $6,549,000 after purchasing an additional 91,911 shares during the last quarter. Finally, Third Avenue Management LLC purchased a new position in Collegium Pharmaceutical during the fourth quarter worth approximately $2,558,000.

Wall Street Analyst Weigh In

COLL has been the subject of a number of recent research reports. Jefferies Financial Group raised Collegium Pharmaceutical from a “hold” rating to a “buy” rating and raised their target price for the stock from $41.00 to $44.00 in a research note on Friday, June 7th. StockNews.com raised shares of Collegium Pharmaceutical from a “buy” rating to a “strong-buy” rating in a research report on Monday, August 12th. Piper Sandler reissued a “neutral” rating and issued a $37.00 price target (down from $39.00) on shares of Collegium Pharmaceutical in a research note on Friday, August 9th. Needham & Company LLC reaffirmed a “hold” rating on shares of Collegium Pharmaceutical in a research report on Friday, August 9th. Finally, Truist Financial boosted their price objective on Collegium Pharmaceutical from $40.00 to $42.00 and gave the company a “buy” rating in a report on Friday, August 9th. Two research analysts have rated the stock with a hold rating, three have given a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $42.00.

Collegium Pharmaceutical Stock Down 0.6 %

NASDAQ:COLL traded down $0.22 during midday trading on Friday, reaching $35.26. The company had a trading volume of 206,394 shares, compared to its average volume of 468,546. Collegium Pharmaceutical, Inc. has a 12-month low of $20.95 and a 12-month high of $40.95. The firm has a market capitalization of $1.15 billion, a price-to-earnings ratio of 14.69 and a beta of 0.93. The company has a current ratio of 1.21, a quick ratio of 1.14 and a debt-to-equity ratio of 1.98. The stock’s fifty day simple moving average is $33.44 and its 200-day simple moving average is $34.91.

Collegium Pharmaceutical (NASDAQ:COLL) last announced its quarterly earnings data on Thursday, August 8th. The specialty pharmaceutical company reported $1.62 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.40 by $0.22. Collegium Pharmaceutical had a return on equity of 104.98% and a net margin of 16.46%. The business had revenue of $145.28 million during the quarter, compared to analysts’ expectations of $143.94 million. During the same quarter last year, the business posted $1.13 EPS. The business’s quarterly revenue was up 7.2% compared to the same quarter last year. On average, sell-side analysts anticipate that Collegium Pharmaceutical, Inc. will post 5.73 earnings per share for the current fiscal year.

Insider Transactions at Collegium Pharmaceutical

In other Collegium Pharmaceutical news, EVP Scott Dreyer sold 56,807 shares of the firm’s stock in a transaction on Friday, May 24th. The stock was sold at an average price of $33.98, for a total value of $1,930,301.86. Following the sale, the executive vice president now directly owns 105,902 shares in the company, valued at $3,598,549.96. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. In other news, EVP Scott Dreyer sold 56,807 shares of the business’s stock in a transaction that occurred on Friday, May 24th. The shares were sold at an average price of $33.98, for a total transaction of $1,930,301.86. Following the completion of the sale, the executive vice president now owns 105,902 shares in the company, valued at approximately $3,598,549.96. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, CFO Colleen Tupper sold 19,710 shares of the stock in a transaction on Tuesday, May 28th. The shares were sold at an average price of $34.21, for a total transaction of $674,279.10. Following the completion of the transaction, the chief financial officer now directly owns 130,845 shares in the company, valued at $4,476,207.45. The disclosure for this sale can be found here. Corporate insiders own 3.98% of the company’s stock.

Collegium Pharmaceutical Profile

Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain.